Distinct biosignatures associate with survival after chemoimmunotherapy in a randomized, three-arm phase II study in patients with metastatic pancreatic cancer.
Journal of Clinical Oncology(2022)
Key words
metastatic pancreatic cancer,pancreatic cancer,chemoimmunotherapy,three-arm
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined